Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. - Wikidata - wikimedia - TriplyDB

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

http://www.wikidata.org/entity/Q48882820

about

Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments Review article: anti-adhesion therapies for inflammatory bowel disease Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us?Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis Monoclonal antibodies and progressive multifocal leukoencephalopathy Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141 Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis.Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset Emerging viral infections of the central nervous system: part 2 Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.Using genetics to enable studies on the prevention of Alzheimer's disease Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.Natalizumab in the treatment of multiple sclerosis Safety of monoclonal antibodies for the treatment of multiple sclerosis.Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab Integrin targeted therapeutics.Peripherally triggered and GSK-3β-driven brain inflammation differentially skew adult hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to ibuprofen.CD4 cell response to interval therapy with natalizumab.Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis H(1)R expression by CD11B(+) cells is not required for susceptibility to experimental allergic encephalomyelitis Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors.Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis.Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell-Mediated Central Nervous System Autoimmune Disease.Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS.Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship.Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats.An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease.Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.

P2860

Q26770818-4AE9EA8E-D6F1-498D-9BEA-8F67AFBAE6B8 Q26822941-2C19A316-8766-4DE8-A61B-358C1C692629 Q26823444-4575DCA6-B086-41A5-B73C-C351211BEA95 Q26851694-8D2DDB82-6275-448D-8A87-CDD311FD7572 Q26999705-030C747F-4BCA-4A15-950A-6813AFBEAF0E Q27021612-172F81F2-4C9F-40AB-887D-9E576D560F47 Q27022494-A8F5B1EB-7F09-4AD0-948A-D7CBAB4D302E Q28082878-D435115E-1660-434B-AAEC-785CFD56D8C4 Q28270413-EA39F13B-7576-4BA1-9894-19E72D38CBD6 Q28546343-A0140B9E-52D8-45C5-9150-0B17BE80DEBB Q28730755-851FABBD-5AFC-4E77-8365-8C0FF1A2B052 Q28731914-90763BDD-232D-40A9-8E46-0C65B81B4ECE Q28740884-F001E08F-8382-4DC5-90EB-1543DD2C3C03 Q30576988-C4EE4DB1-A41B-4BD0-82FD-0A16AAEE1BE6 Q30659100-574ED8D2-A01D-4DAD-9F6B-CF39939648B8 Q33832088-983260D2-FF3F-4549-9835-7EE7B6188EC5 Q33873941-C928F5C4-08D0-4F8C-AB30-8D945E942EE5 Q33877744-641AF4DB-18DF-47DE-8B0A-503FF8511F41 Q33975585-B2C73062-4FA7-4E63-8EC5-088C211CC996 Q34038890-2A2C3275-856A-4997-A87F-4C4294E5A1E3 Q34135724-B120E205-D348-4E4A-BA77-439D288F33F1 Q34230150-3A40F078-5731-4F9C-B6B8-09B955B1119E Q34243433-33751C67-92F7-4FF3-86A4-D915516B45B0 Q34409340-B9F55DF2-9544-48C6-A471-DAA8B9616C34 Q34542922-18474BB9-E0B2-4C0F-A27B-87FC5964612C Q34818048-ED787B70-73EC-4B38-8E05-D05927B6674D Q34912684-AE0D9060-0153-4894-B737-CD7014E8233A Q35150206-2B303D84-5545-464A-8B38-99B59761584E Q35619220-5ED6505E-6FEF-433A-BE59-D02BCED7EF48 Q35669064-98B81BCB-1CB8-45D4-B226-175C8440ACE5 Q35957449-2820D7D8-6D3A-40F9-A151-9EDEEFFA9D6B Q36374681-95188981-4FBE-4946-AF6F-21EDA235E4DB Q36379542-DB6027CB-C0F7-4BDD-8236-ADF14FDA8562 Q36416627-5BA6CDC4-C371-4B13-A315-A9A9107155D2 Q36553718-5DF73662-E75E-4460-AB7E-E6166B3B4C04 Q36884649-5E282427-8C5F-4345-8CE2-D28C919CFB45 Q37069901-AF968E9E-5676-46D8-8F73-A64A5E09FB60 Q37083046-0EAFCAA0-6674-441A-B66F-222C62A701B2 Q37546119-4A1E72D7-7141-4A74-B90F-E8B18371C560 Q37696989-19C0F136-5E55-43E5-981D-DEFBEA1FBE5B

P2860

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

http://www.wikidata.org/entity/Q48882820

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Decrease in the numbers of den ...... lar spaces due to natalizumab.

@en

Decrease in the numbers of den ...... lar spaces due to natalizumab.

@nl

type

label

Decrease in the numbers of den ...... lar spaces due to natalizumab.

@en

Decrease in the numbers of den ...... lar spaces due to natalizumab.

@nl

prefLabel

Decrease in the numbers of den ...... lar spaces due to natalizumab.

@en

Decrease in the numbers of den ...... lar spaces due to natalizumab.

@nl

P1433

Q48882820-4E62BCE4-CB59-42A1-A7DB-134E57821B01

P1476

Q48882820-EB3E2203-012D-45F8-B6D9-7819C65F6772

P2093

Q48882820-4DC63E83-F1AC-406E-A54E-ADB40C6195B9

Q48882820-5E81A037-50A8-4C8E-B465-EFE8FF900610

Q48882820-64EE6ECF-BA95-4F55-A08F-2D2FE843904B

Q48882820-6BB01E4C-62C8-469B-B306-CC5E7C049489

Q48882820-A1BDC7BA-CFC9-4B4C-B9BB-88D9FF031901

Q48882820-C7BE251C-BCC2-4A8D-A742-0AB2DDDC8149

Q48882820-D078324C-D902-45EF-8E53-A61733C99545

Q48882820-D5C19D2F-F7E9-4C1C-839F-1C61BA13C265

Q48882820-DEB7751D-4F65-4EC8-A03D-149E62448692

Q48882820-E2A6D96D-CDC5-4829-B6E7-F8D6A0177211

P304

Q48882820-2E8708E7-EB6C-4344-8030-BBD022A94ECE

P31

Q48882820-0620C1E6-218A-437C-82AB-EDCF060DD605

P356

Q48882820-FCFED147-6ED5-452E-92D0-0257B4912ED2

P433

Q48882820-3B9AF26C-B145-4173-A772-511C5B2DCA89

P478

Q48882820-B471F497-C570-4C91-986B-D81385E11885

P50

Q48882820-6285FEBA-9294-479A-AE48-07E3CA29477B

P577

Q48882820-C7AD14E8-A814-4E39-8099-F724E4DB6C56

P5875

Q48882820-3472388A-9744-45E8-944D-666191BCEB3A

P698

Q48882820-85D03048-E9FC-474E-A06C-966A2F8030AC

P356

ARCHNEUR.65.12.NOC80051

P1433

P1476

Decrease in the numbers of den ...... lar spaces due to natalizumab.

@en

P2093

B K Kleinschmidt-DeMasters

http://www.w3.org/2001/XMLSchema#string

Bernhard Hemmer

http://www.w3.org/2001/XMLSchema#string

Elliot M Frohman

http://www.w3.org/2001/XMLSchema#string

Maria del Pilar Martin

http://www.w3.org/2001/XMLSchema#string

Martin S Weber

http://www.w3.org/2001/XMLSchema#string

Michael K Racke

http://www.w3.org/2001/XMLSchema#string

Nitin J Karandikar

http://www.w3.org/2001/XMLSchema#string

Petra D Cravens

http://www.w3.org/2001/XMLSchema#string

Ryan Winger

http://www.w3.org/2001/XMLSchema#string

Scott S Zamvil

http://www.w3.org/2001/XMLSchema#string

P304

1596-1603

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUR.65.12.NOC80051

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23314620

http://www.w3.org/2001/XMLSchema#string

P698

18852339

http://www.w3.org/2001/XMLSchema#string